VANFLYTA 17.7 mg and 26.5 mg film-coated tablets
*Company:
Daiichi Sankyo Ireland LtdStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 06 February 2026
File name
vanflyta-pil-ie-v03-2602-clean.pdf
Reasons for updating
- Change to further information section
Free text change information supplied by the pharmaceutical company
Update of Local Representatives in number of EU countries
File name
DSE_VANFLYTA_PatientCard_Selfprint_A4_IE_view.pdf
Reasons for updating
- New EDM File
File name
DSE_VANFLYTA_HCP Guide_IE_final0912_view Dec.pdf
Reasons for updating
- New EDM File
Updated on 16 January 2025
File name
vanflyta-smpc-ie-v04-241216-clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 16 January 2025
File name
vanflyta-pil-ie-v02-2405 clean.pdf
Reasons for updating
- New PIL for new product
Daiichi Sankyo Ireland Ltd
Address:
Unit 29, Block 3, Northwood Court, Northwood Avenue, Santry, Dublin 9, IrelandMedical Information E-mail:
medinfo-ie@daiichisankyo.comTelephone:
+353 1 489 3000